Merck KGaA has agreed to acquire US-based life-sciences provider Bio-Techne for $11.3 billion, marking one of the largest transactions in the German company's history.
The deal significantly expands Merck’s presence in the laboratory equipment and research tools sector, diversifying its portfolio beyond traditional pharmaceuticals and chemicals.
The $11.3 billion price tag underscores the premium placed on specialized biotech infrastructure, as large-cap players compete for access to essential research capabilities.
The acquisition targets Bio-Techne’s extensive catalog of reagents, antibodies, and cell culture products, which are critical for academic and industrial research.
By integrating these assets, Merck aims to strengthen its position in the high-growth life-sciences market, where demand for advanced research tools remains robust despite broader economic headwinds.
This move reflects a strategic shift for the DAX-listed conglomerate, which has been seeking to bolster its growth profile through targeted M&A activity.
The $11.3 billion price tag underscores the premium placed on specialized biotech infrastructure, as large-cap players compete for access to essential research capabilities.